The rapid growth in biopharmaceutical development brings a myriad of new challenges for bioanalysts, not present in small molecules analysis. The application examples below outline methods, inclusive of sample prep, separations, MS and informatics, which enable scientists to solve the most pressing and challenging analytical problems related to biopharmaceutical bioanalysis. Waters Xevo Mass Spectrometry Solutions Integrate:
|
|
Peptide and Protein Bioanalysis Application Notebook |
|
|
Peptides and Proteins are not Small Molecules; Why Treat Them the Same? Whether you have been doing it for years or are just starting off, large molecule quantification creates a number of challenges for bioanalysts, including:
Waters’ Peptide and Protein Bioanalysis Application Notebook is the most comprehensive collection of peptide and protein bioanalysis applications available. With over 48 unique analytes and with insights from 60 expert authors, you will find guidance on your most pressing bioanalytical challenges. |
Application Notebook |
|
Key Challenges of Peptide and Protein Bioanalysis |
|
|
Large molecule quantitation is one of the greatest challenges that bioanalysts face. Sensitivity and specificity issues are numerous such as fewer molecules per volume, increased fragmentation and limited recovery due to complex sample prep, to name a few. Learn more about these key challenges in this infographic. |
Infographic Peptides and Proteins are Not Small Molecules: Why Treat Them The Same?
Learn more |
|
Quantitation of Monoclonal Antibodies |
|
Monoclonal antibodies (mAbs) comprise an expanding group of therapeutic compounds, which are used to treat cancer, auto-immune diseases, and systemic infections. Mass spectrometry is the analytical tool of choice for quantitation of mAbs, due to its selectivity, multiplexing, and dynamic range advantages over ligand binding assays (LBAs). Waters' Xevo tandem quad family, columns and chemistries have been used to conduct bioanalysis of large protein molecules, such as the monoclonal antibodies and antibody-drug conjugates (ADCs) like Bevacizumab, Infliximab, and Trastuzumab Emtansine . ProteinWorks are a set of kits that facilitate the surrogate peptide method (protein digest), which is the most common method for mAb quantitation by LC/MS. This notebook contains key examples of accurate, sensitive, and reproducible quantitation of protein therapeutics including mAbs and ADCs. |
|
Application Notebook |
|
Drug Metabolism and Pharmacokinetics (DMPK) |
|
Due to its superior mass resolution abilities, high resolution mass spectrometry (HRMS) is now being used to overcome bioanalytical quantitation challenges facing small and large molecule development portfolios. This includes the ability to develop validated methods in drug development, overcoming selectivity challenges and the intact analysis of large molecules |
|
Webcast Learn more |
|
Therapeutic monitoring of Bradykinin |
|
Bradykinin is an inflammatory mediator and an important regulator of blood pressure, kidney function and heart function, and also involved in inflammation. The ability to measure changes of this peptide hormone with high sensitivity, selectivity and accuracy, as a function of disease progression or drug treatment is highly advantageous. LC-MS/MS using a Xevo tandem quadrupole mass spectrometer has the advantages of shorter development times, greater accuracy and precision, the ability to multiplex, and can readily distinguish between closely related analogues, metabolites or endogenous interferences. |
|
Application Note Development of a Quantitative SPE LC-MS/MS Assay for Bradykinin in Human Plasma. |
|
Microflow LC/MS for Peptide and Protein Quantitation |
|
|
Microflow can facilitate sensitivity gains for a wide variety of analytes, but the greatest benefit has been for peptides and proteins. Peptide and protein bioanalysis brings greater complexity compared to small molecule analysis. High background noise due to endogenous peptides and proteins can reduce signal and require more complex sample prep. Larger molecules have more multiply-charged species, increased fragmentation patterns, and a variety of lower abundance fragments, all of which reduce signal-to-noise ratio. Additionally, a significant number of biologics have longer half-lives than small molecules; therefore, many are dosed at low concentrations. These issues associated with large molecule bioanalysis support the need for the sensitivity afforded by modern microflow LC/MS. |
Webinar Application Note |
|
For More Quantitative Content Visit our DMPK and Bioanalysis Knowledge Center |